Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Double-Edged Sword: Urbanization and Response of Amniote Gut Microbiome in the Anthropocene.Microorganisms · 2025
   Review
2. The Role of Lactoferrin in Intestinal Health.Pharmaceutics · 2023
   Review
3. Astragalin Attenuates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis by Alleviating Gut Microbiota Dysbiosis and Inhibiting NF-κB Activation in Mice.Frontiers in immunology · 2020
   Article
4. Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study.Gut microbes
   Article

Corrections and comments

• Erratum for
  NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.2017

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract